Perseus Proteomics Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-786	-902	-1,102	-785	-597	-411
Depreciation & Amortization	-	2	3	5	2	-
Loss (Gain) From Sale of Assets	38	72	153	95	117	1
Other Operating Activities	47	-1	-1	-	-	-
Change in Accounts Receivable	-7	-8	-3	-	-1	1
Change in Inventory	-4	-	-1	-	-1	-
Change in Accounts Payable	-8	8	1	22	10	-23
Change in Other Net Operating Assets	38	110	117	99	-6	10
Operating Cash Flow	-682	-719	-833	-564	-476	-422
Capital Expenditures	-28	-75	-143	-164	-33	-2
Sale (Purchase) of Intangibles	-	-	-15	-6	-	-
Other Investing Activities	-	-	8	-42	-	-
Investing Cash Flow	-28	-75	-150	-212	-33	-2
Issuance of Common Stock	3	927	63	-	2,652	1,011
Other Financing Activities	1	-4	-	-	-5	-
Financing Cash Flow	4	923	63	-	2,647	1,011
Foreign Exchange Rate Adjustments	7	-2	16	7	8	1
Miscellaneous Cash Flow Adjustments	-2	-1	1	-	-1	-2
Net Cash Flow	-701	126	-903	-769	2,145	586
Free Cash Flow	-710	-794	-976	-728	-509	-424
Free Cash Flow Margin	-586.78%	-661.67%	-976.00%	-774.47%	-716.90%	-632.84%
Free Cash Flow Per Share	-48.16	-55.65	-82.80	-61.91	-46.29	-60.57
Cash Income Tax Paid	2	1	1	1	1	1
Levered Free Cash Flow	-574.5	-592.25	-736.38	-631.63	-249.63	-269.5
Unlevered Free Cash Flow	-574.5	-592.25	-736.38	-631.63	-249.63	-269.5
Change in Working Capital	19	110	114	121	2	-12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.